These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 14684147)
1. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Gertz MA; Lacy MQ; Dispenzieri A Blood Rev; 2004 Mar; 18(1):17-37. PubMed ID: 14684147 [TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357 [TBL] [Abstract][Full Text] [Related]
4. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974 [TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Gertz MA Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896 [TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP; N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669 [TBL] [Abstract][Full Text] [Related]
8. [Current treatment of AL amyloidosis]. Kovacsovics T Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088 [TBL] [Abstract][Full Text] [Related]
10. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082 [TBL] [Abstract][Full Text] [Related]
11. New and developing therapies for AL amyloidosis. Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971 [TBL] [Abstract][Full Text] [Related]
12. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Schonland SO; Perz JB; Hundemer M; Hegenbart U; Kristen AV; Hund E; Dengler TJ; Beimler J; Zeier M; Singer R; Linke RP; Ho AD; Goldschmidt H Transplantation; 2005 Sep; 80(1 Suppl):S160-3. PubMed ID: 16286897 [TBL] [Abstract][Full Text] [Related]
13. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Kyle RA; Greipp PR; Garton JP; Gertz MA Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968 [TBL] [Abstract][Full Text] [Related]
14. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810 [TBL] [Abstract][Full Text] [Related]
15. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM; Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441 [TBL] [Abstract][Full Text] [Related]